文献速递治疗药物监测与药物基因组学

长读长测序通过解析复杂单倍型、新星号等位基因和结构变异提升药物基因组学分析

Long-Read Sequencing Enhances Pharmacogenomic Profiling by Resolving Complex Haplotypes, Novel Star Alleles, and Structural Variants.
PubMed 文献 · Clin Pharmacol Ther · 2025-11-27

该研究利用Oxford Nanopore或PacBio长读长测序数据,分析100名1,000 Genomes Project健康个体和159名Genomics England癌症与罕见病队列参与者的20个临床可操作药物基因的双单倍型和药物反应表型。长读长测序定相准确率超过98%(Oxford Nanopore)和96.5%(PacBio),鉴定出19个新星号等位基因和106个新亚等位基因,并重新分配了100名1,000 Genomes Project受试者中58人的77个基因型。结果表明长读长测序在解析复杂基因组区域方面优于短读长测序,可实现更精准的药物基因组学分析。

要点

  • 长读长测序定相准确率>98%(Oxford Nanopore)和96.5%(PacBio),变异检测精确率、召回率和F1均>0.92。
  • 长读长测序在9个药物基因中鉴定出19个新星号等位基因和106个新亚等位基因,并解析了13个模糊的CYP2D6结构变异。
  • 长读长测序重新分配了100名1,000 Genomes Project受试者中58人的77个基因型,短读长预测对不一致病例的贡献近长读长的两倍。

核心结论

  • 长读长测序在定相和解析复杂基因组区域方面优于短读长测序,可实现更精准的药物基因组学分析。

研究设计与样本

  • 研究分析100名1,000 Genomes Project健康个体和159名Genomics England癌症与罕见病队列参与者的20个临床可操作药物基因,使用Oxford Nanopore或PacBio长读长数据及Illumina短读长数据。

主要发现

  • 长读长测序定相准确率>98%(Oxford Nanopore)和96.5%(PacBio),多数基因覆盖于单个定相单倍型块。
  • 变异检测精确率、召回率和F1均>0.92,短读长与长读长预测的基因型和表型一致性超过99%。
  • 短读长预测对总体不一致病例的贡献近长读长的两倍。
  • 长读长测序在9个药物基因中鉴定出19个新星号等位基因和106个新亚等位基因,包括CYP2D6、CYP2B6、CYP2C9、CYP2C19、CYP4F2和SLCO1B1,已提交至PharmVar。
  • 长读长测序解析了13个模糊的CYP2D6结构变异(包括一个潜在新结构),并鉴定出与弱代谢者表型相关的纯合TA重复(UGT1A1*80 + *28)。

临床怎么用

  • 长读长测序可提高药物基因组学检测的定相和结构变异解析能力,减少模糊单倍型和错误表型预测。
  • 随着测序成本下降,长读长测序可能成为临床药物基因组学的首选方法,提升治疗安全性和有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pharmacogenomics has shifted drug therapy from trial-and-error to personalized approaches by leveraging genetic biomarkers. However, traditional genotyping assays and short-read sequencing often fail to resolve structural complexity in pharmacogenes, leading to ambiguous haplotypes and incorrect phenotype predictions. To evaluate the potential of emerging long-read sequencing technologies in overcoming these limitations, we analyzed diplotypes and drug response phenotypes across 20 clinically actionable pharmacogenes using Oxford Nanopore or PacBio data from 100 healthy individuals in the 1,000 Genomes Project and 159 participants from the Genomics England cancer and rare disease cohorts, alongside Illumina short-read sequencing data. Long reads achieved phasing accuracies of >98% (Oxford Nanopore) and 96.5% (PacBio), with most genes covered by a single phased haploblock. Variant detection metrics were high (i.e., precision, recall, and F1 > 0.92). Genotype and phenotype concordance between short- and long-read predictions exceeded 99%. Short-read predictions contributed nearly twice as much to overall discordant cases compared to those of long reads. Notably, long reads identified 19 novel star (*) alleles and 106 novel suballeles in nine pharmacogenes, including CYP2D6, CYP2B6, CYP2C9, CYP2C19, CYP4F2, and SLCO1B1, which have been submitted to PharmVar. Additionally, long reads resolved 13 ambiguous CYP2D6 structural variants, including a potentially novel structure. Also, a homozygous TA repeat (UGT1A1*80 + *28) was identified that is associated with a poor metabolizer phenotype. Overall, we reassigned 77 genotypes across nine genes for 58 of the 100 investigated 1,000 Genomes Project subjects. These results demonstrate the superiority of long-read sequencing in phasing and resolving complex genomic regions enabling more precise pharmacogenomic profiling. As sequencing costs decline with rapid technological advances, long-read sequencing may become the method of choice in clinical pharmacogenomics, enhancing therapeutic safety and efficacy.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Samarasinghe SR, Gaedigk A, Swen JJ, et al. Long-Read Sequencing Enhances Pharmacogenomic Profiling by Resolving Complex Haplotypes, Novel Star Alleles, and Structural Variants. Clin Pharmacol Ther. 2025. PMID: 41311006. doi:10.1002/cpt.70115

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。